The Evolving Science and Medicine of Incretin-Based Therapy for Type 2 Diabetes: Options, Strategies, and Combinations
Charles Faiman, MD, FRCPC, MACE

The Current Armamentarium of Oral Agents for Type 2 Diabetes Mellitus—Sequencing Oral Therapy
Samir Malkani, MD

New Mechanisms of Action for Oral Agents in Type 2 Diabetes: Applying Novel Therapies to Clinical Practice
Charles Faiman, MD, FRCPC, MACE

Sequencing Oral Therapy in Type 2 Diabetes: DPP-4 Inhibitors as Monotherapy or Combination Therapy with Metformin, Sulfonylureas, and TZDs—Constructing Outcome-Optimizing Oral Regimens
Alexander Turchin, MD, MS

Cardiovascular, Metabolic, and Renal Considerations: Optimizing Efficacy and Safety of DPP-4 Inhibitor Therapy in High Risk Patients
Derek LeRoith, MD, PhD, FACP

Interactive Question and Answer Session
Faculty Panel